CD4 and COVID-19: This observation further corroborates recent findings showing that as in individuals convalescing from COVID-19 who develop effective CD4 and CD8 T cells responses [32], the BNT162b2 mRNA vaccine triggers not only humoral but also cellular immunity (poly-specific T cells) [41, 42].